IL-5介导甲磺酸伊马替尼诱发的红皮病型药疹一例并文献复习  

Erythrodermic drug eruption induced by IL-5-mediated imatinib mesylate and literature review

作　　者：王田宇 鲁阳 孙乐乐[1] 孙勇虎[1] WANG Tianyu;LU Yang;SUN Lele;SUN Yonghu(Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Venereology,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250022,China)

机构地区：[1]山东第一医科大学附属皮肤病医院(山东省皮肤病医院),山东省皮肤病性病防治研究所,山东济南250022

出　　处：《中国麻风皮肤病杂志》2023年第10期713-715,共3页China Journal of Leprosy and Skin Diseases

基　　金：国家自然科学基金面上项目(编号:82073441);山东省泰山学者青年专家计划(编号:tsqn201909141)。

摘　　要：报道一例胃间质瘤患者服用甲磺酸伊马替尼7个月后全身泛发红斑脱屑、眶周水肿、指甲甲板增厚色沉等红皮病样表现,给予环孢素口服,2周后皮损好转,检测其治疗前后12项免疫因子发现IL-1β、IL-5及IFN-γ显著下降,其中IL-5从治疗前1811 pg/mL降至36.22 pg/mL,表明IL-5在甲磺酸伊马替尼诱发不良反应中发挥重要作用,提示靶向IL-5的生物制剂可能是治疗该病的潜在药物。We reported a case of a patient with gastric stromal tumor who presented with generalized erythematous desquamation,periorbital edema,and thickened,discolored nail plates after 7 months of treatment with imatinib mesylate.The patient was given oral cyclosporine,and the lesions subsided after 2 weeks.Analysis of 12 cytokines before and after treatment revealed a significant decrease in IL-1β,IL-5,and IFN-γ.Particularly,IL-5 decreased from 1811 pg/mL before treatment to 36.22 pg/mL,suggesting an important role of IL-5 in the adverse reactions induced by imatinib mesylate.This finding suggests that biologics targeting IL-5 may be potential drugs to treat the disease.

关 键 词：甲磺酸伊马替尼 红皮病型药疹 IL-5 

分 类 号：R969[医药卫生—药理学]